News
Displaying 171–180 of 504
-
In the Press
Raffaella Toso, PhD, joins as VP Corporate Development & Alliance Management and Florence Paliargues appointed as VP Portfolio Project Management.
-
RD Fund Announces Fundraising Efforts Underway for RD Fund 2
Foundation NewsPatient-centric venture philanthropy model continues to invest in companies developing therapies for individuals affected by retinal degenerative diseases.
-
FDA Approves Genentech’s Susvimo for Treating Wet AMD
Research NewsThe approach significantly reduces the need for regular ocular injections.
-
Opus Genetics Announces Two Key Leadership Appointments
In the PressDr. Ash Jayagopal named Chief Scientific Officer and Mr. Joe Schachle appointed Chief Operating Officer.
-
Atsena Therapeutics Developing X-Linked Retinoschisis Gene Therapy
Research NewsThe emerging gene therapy is being designed to more safely reach the fovea
-
Foundation Fighting Blindness Appoints Richele Donat, SPHR, as Chief Human Resources Officer
Foundation NewsMs. Donat brings over twenty years of successful human resource leadership experience to the Foundation executive team
-
Foundation Hosts Workshop on USH1B Research and Therapy Development
Research NewsEmerging dual-vector gene therapies to address current cargo-size limitations were highlighted during the meeting.
-
Covid Revealed What Science Can Do When Funding is Found
In the Press‘In some ways, the pandemic ought to make us all feel more upbeat about the long-term future of medical research.’
-
RD Fund Appoints Tony Adamis, MD to Board of Directors
Foundation NewsThe RD Fund announces the appointment of Anthony (Tony) Adamis, MD, to its board of directors.
-
Research News
The emerging treatment targets a specific mutation (c.2991+1655A>G in Intron 26) of the gene CEP290 which causes Leber congenital amaurosis 10 (LCA 10)
.png)
